Dernière mise à jour :
18/04/2024
Divers   Aminophylline  
Injectable
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Aminocardol Turquie
Aminodic Iran
Aminofilina Argentine, Chili, Colombie, Equateur, Italie, Mexique, Pérou, Portugal, Vénézuela
Aminomal Italie
Aminophyllin Malaisie, Norvège, Suisse
Aminophylline Arabie Saoudite, Australie, Canada, Etats Unis d’Amérique, Grande Bretagne, Grèce, Iran, Irlande, Malaisie
Aminophyllinum Pologne
Amipine Malaisie
Amofilin Colombie, Mexique
Broncophilina Vénézuela
Diaphyllin Hongrie
Drafilyn Mexique
Euphyllin Arabie Saoudite, Autriche, Luxembourg, Pays bas, Suisse
Euphyllina Italie
Fadafilina Argentine
Minophyline Egypte
Minotec Mexique
Miofilin Roumanie
Neophyllin Japon
Tecar Turquie
Tefamin Italie
Teofillina Italie
Teofylamin Danemark
Teofyllamin Suède
Teolin Iran
Bibliographie   Injectable   Bibliographie : Aminophylline  
Type Source
3 Revue Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Revue Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73 Revue Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Revue Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Revue Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
91 Revue Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
96 Revue Stewart JT, Warren FW, Johnson SM.
Stability of cefuroxime sodium and aminophylline or theophylline.
Am J Hosp Pharm 1994 ; 51: 809-811.
99 Revue Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Revue Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
174 Revue Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO.
Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride.
Am J Hosp Pharm 1990 ; 47: 1567-1571.
182 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
187 Revue Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS.
Stability of flumazenil with selected drugs in 5% dextrose injection.
Am J Hosp Pharm 1993 ; 50: 1907-1912.
198 Revue Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
210 Revue Stewart JT, Warren FW, King AD.
Stability of ranitidine hydrochloride and seven medications.
Am J Hosp Pharm 1994 ; 51: 1802-1807.
214 Revue Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ.
Stability of ranitidine hydrochloride with eight medications in intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 1606-1610.
215 Revue Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426.
244 Revue Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Revue Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Revue Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
262 Revue Johnson CE, Jacobson PA, Pillen HA, Woycik CL.
Stability and compatibility of fluconazole and aminophylline in intravenous admixtures.
Am J Hosp Pharm 1993 ; 50: 703-706.
266 Revue Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
276 Revue Parrish MA, Bailey LC, Medwick T.
Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures.
Am J Hosp Pharm 1994 ; 51: 92-94.
288 Revue Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
299 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Revue Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
315 Revue Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 Revue Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334 Revue Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
364 Revue Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ.
Compatibility of aminophylline and verapamil in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 97-100.
384 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632.
386 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
390 Revue Johnson CE, Cohen IA, Craft DA, Lizer MH.
Compatibility of aminophylline and methylprednisolone sodium succinate intravenous admixtures.
Am J Hosp Pharm 1986 ; 43: 1482-1485.
396 Revue Chilvers MR, Lysne JM.
Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications.
Am J Hosp Pharm 1989 ; 46: 2057-2058.
397 Revue Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126.
402 Revue Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
434 Revue Goodwin SD, Nix DE, Heyd A, Wilton JH.
Compatibility of ciprofloxacin injection with selected drugs and solutions.
Am J Hosp Pharm 1991 ; 48: 2166-2171.
478 Revue Nahata MC, Morosco RS, Hipple TF.
Stability of aminophylline in bacteriostatic water for injection stored in plastic syringes at two temperatures.
Am J Hosp Pharm 1992 ; 49: 2962-2963.
479 Revue Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
492 Revue Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Revue Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
539 Revue Baptista RJ, Mitrano FP.
Stability and compatibility of cimetidine hydrochloride and aminophylline in dextrose 5% in water injection.
Drug Intell Clin Pharm 1988 ; 22: 592-593.
619 Revue Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ.
Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.
Am J Hosp Pharm 1982 ; 39: 1013-1015.
706 Revue Cutie MR.
Compatibility of verapamil hydrochloride with other additives.
Am J Hosp Pharm 1981 ; 38: 231.
730 Revue Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943.
900 Revue Pleasants RA, Vaughan LM, Williams DM, Fox JL.
Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion.
Ann Pharmacotherapy 1992 ; 26: 1221-1226.
905 Revue Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
939 Revue Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
1036 Revue Hasegawa GR, Eder JF.
Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041 Revue Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1049 Revue Klamerus KJ, Ueda CT, Newton DW.
Stability of nitroglycerin in intravenous admixtures.
Am J Hosp Pharm 1984 ; 41: 303-305.
1058 Revue Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072 Revue Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1188 Revue Niemiec PW, Venderveen TW, Hohenwarter MW, Gadsden RH.
Stability of aminophylline injection in three parenteral nutrient solutions.
Am J Hosp Pharm 1983 ; 40: 428-432.
1193 Revue Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ.
Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.
Am J Hosp Pharm 1983 ; 40: 1010-1012.
1232 Revue Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1236 Revue Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242.
1259 Revue Jhunjhunwala VP, Bhalla HL.
Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection.
Am J Hosp Pharm 1981 ; 38: 900-901.
1315 Revue Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Revue Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1490 Revue Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496 Revue Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Revue Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1712 Revue Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Revue Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Revue Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Revue Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Revue Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888 Revue Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A.
Compatibility study of midazolam.
Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925 Revue Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1953 Revue Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Revue Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018 Revue Veggeland T.
Visual compatibility of clonidine with selected drugs.
Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087 Revue Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Revue Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2108 Revue Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2109 Revue Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2262 Revue Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Revue Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3152 Revue Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3249 Revue Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372 Revue Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3408 Revue Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3525 Laboratoire Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012
3526 Laboratoire Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3531 Laboratoire Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3543 Laboratoire Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3548 Laboratoire Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3588 Laboratoire Vancomycine (Vancocin®) - Résumé des caractéristiques du produit
Sandoz 2011
3602 Laboratoire Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3612 Laboratoire Doxapram (Dopram) - Summary of Product Characteristics
Amdipharm Mercury Company 2012
3646 Laboratoire Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2013
3674 Laboratoire Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3696 Revue Santos C.A.D, Oliveira-Nascimento L, Knirsch M.C, Stephano M.A, Pessoa J?nior A, Penna T.C.V.
Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution.
Braz J Pharm Sci 2012 ; 48, 4: 691-698.
3759 Revue Igarashi K, Kawahara M.
Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier.
Yakugaku Zasshi 2014 ; 134, 2: 293-298.
3766 Revue Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3824 Revue Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
4154 Laboratoire Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4389 Revue Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4528 Revue Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Revue Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 Revue Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales